Strata Critical Medical grants 50,234 RSUs to director

WIESENTHAL ROBERT S reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

WIESENTHAL ROBERT S reported acquisition or exercise transactions in this Form 4 filing.

Strata Critical Medical, Inc. reported that director Robert S. Wiesenthal received a grant of 50,234 Restricted Stock Units (RSUs) of Class A common stock on 2026-07-30. These RSUs will be settled in shares upon vesting, with 100% vesting on the date of the company’s 2027 Annual Meeting of Stockholders. Following this award, Wiesenthal holds 5,325,896 shares of Class A common stock. The award carries a stated price of $0.0000 per share, reflecting a non-cash equity grant.

Insider Trade Summary

Grant/Award: 50,234 shares

Grant/Award 1 txn

Insider WIESENTHAL ROBERT S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A common stock, $0.0001 par value per share F1	50,234	$0.00	$0.00

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 5,325,896 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders.

Key Figures

RSUs granted: 50,234 shares Grant price per share: $0.0000 Shares following transaction: 5,325,896 shares +1 more

4 metrics

RSUs granted 50,234 shares Restricted Stock Units granted to director on 2026-07-30

Grant price per share $0.0000 Stated per-share price for the non-cash RSU equity award

Shares following transaction 5,325,896 shares Total Class A common stock held by Robert S. Wiesenthal after the award

Vesting event 2027 Annual Meeting of Stockholders 100% of the 50,234 RSUs vest on this meeting date

Key Terms

Restricted Stock Units, Class A common stock, par value, Annual Meeting of Stockholders

4 terms

Restricted Stock Units financial

"Represents a grant of Restricted Stock Units ("RSUs"), which will be settled"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A common stock financial

"Class A common stock, $0.0001 par value per share"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

par value financial

"Class A common stock, $0.0001 par value per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

Annual Meeting of Stockholders financial

"100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SRTA director Robert S. Wiesenthal report?

Director Robert S. Wiesenthal reported receiving a grant of 50,234 Restricted Stock Units (RSUs) of Strata Critical Medical, Inc. Class A common stock. The RSUs are equity awards that will be settled in shares of common stock when they vest in 2027.

How many Strata Critical Medical (SRTA) shares does Robert S. Wiesenthal hold after this grant?

After the RSU grant, Robert S. Wiesenthal is reported as holding 5,325,896 shares of Strata Critical Medical Class A common stock. This figure reflects his direct ownership position immediately following the 50,234-unit RSU award on 2026-07-30.

When do the 50,234 RSUs granted by SRTA to Robert S. Wiesenthal vest?

All 50,234 RSUs will vest 100% on the date of Strata Critical Medical’s 2027 Annual Meeting of Stockholders. Once vested, the RSUs will be settled in shares of the company’s common stock, increasing his share-based holdings.

Was any cash paid for the SRTA RSU grant to Robert S. Wiesenthal?

No cash was paid for the RSU grant; the transaction shows a price of $0.0000 per share. This indicates the 50,234 RSUs were issued as a non-cash equity award, typical of director or executive compensation arrangements.

Will the SRTA RSUs granted to Robert S. Wiesenthal be settled in stock or cash?

The 50,234 RSUs will be settled in shares of Strata Critical Medical’s common stock upon vesting. The footnote specifies that each Restricted Stock Unit converts into common shares when vesting occurs at the company’s 2027 Annual Meeting of Stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:07 PM Accepted by SEC EDGAR 08/03/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIESENTHAL ROBERT S

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

666 THIRD AVENUE, 25TH FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	07/30/2026		A		50,234(1)	A	$0	5,325,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders.

Remarks:

	/s/ Melissa M. Tomkiel, Attorney-in-fact for Robert S. Wiesenthal	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)